USFDA grants Orphan Drug Designation for iOnctura's first-in-class autotaxin cancer therapy
It is the first autotaxin inhibitor to be investigated in cancer patients
It is the first autotaxin inhibitor to be investigated in cancer patients
The institution will be spread over an area of more than 8 acres
The company will provide comprehensive response to USFDA for the observations
The plan is to set up an ultramodern Solvent Recovery Plant for third party purposes
The validations confirm the completion of the applications and commence the scientific review process
The facility will manufacture Specialty and Fine Chemicals tailored to various applications across industries such as Polymer and Water Treatment facilities
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Neurontin Tablets, 600 mg and 800 mg, of Viatris Specialty
Connecting new production and consumption areas of chilled food by low-carbon transportation services
Launch of Indian public health standards for Ayush healthcare facilities
Subscribe To Our Newsletter & Stay Updated